Global cuts to HIV research and support funding have the Joint United Nations Programme on HIV and AIDS (UNAIDS) worried ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following ...

The third study, Twiga , is an ongoing five-year observational study tracking comorbidities in both HIV-positive and HIV-negative individuals aged 60 and above. It was initiated to better understand ...

Popular global HIV/AIDS program PEPFAR has been spared as Congress passes a package with billions of dollars in spending cuts ...

A University of Colorado professor who experienced a funding freeze firsthand this year expressed relief at the program's preservation.

Kenya is among nine African countries, under the low- and middle-income category, that are set to be among the early beneficiaries of lenacapavir, a long-acting HIV prevention drug, following a recent ...

: WHO-approved HIV preventive drug Lenacapavir to be rolled out next year to allow for changes in existing guidelines and ...

Kenya is set to introduce a revolutionary injectable HIV prevention drug, Lenacapavir, becoming one of nine African nations ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention as a tool ...

Kenya has been picked among nine countries for the trials of the new injectable HIV prevention drug that has been rolled out ...

Kenya’s femicide crisis is so pervasive that even female police officers are not immune –– such as victim and mother-of-two ...